Case fatality rate 1.2% without co-morbidities, 18% with them, says Government data

Case fatality rate 1.2% without co-morbidities, 18% with them, says Government data

24
0
SHARE


(This story originally appeared in on Oct 14, 2020)

NEW DELHI: The overall case fatality rate of people with co-morbidities like diabetes, hypertension, renal and heart diseases and cancer is 17.9 per cent, while it is 1.2 per cent for those without co-morbidities, according to health ministry data. Overall deaths due to the infection in India remain at 1.5 per cent of total confirmed cases.

Till Monday, India recorded 1,09,856 deaths due to Covid-19, whereas the total confirmed cases of the infection stood at 71,75,880. Over 62.27 lakh patients have recovered from the disease so far.

Deaths

The latest age-wise analysis of Covid-19 mortality by the health ministry showed that those in the younger age band were more vulnerable to the disease, though the fatality rate continues to be higher at 53 per cent among people over 60 years of age.

About 47 per cent of Covid-19 deaths have been recorded among those aged below 60 years and patients aged 45-60 accounted for a substantial 35 per cent of total deaths.

About 70 per cent Covid-19 deaths have been of male patients while 30 per cent was reported in females.

Secretary in the health ministry Rajesh Bhushan said in the age group of 60 years and above, 24.6 per cent of the victims had co-morbidities while 4.8 per cent had no co-morbidity.

In the age group of 45-60 years, 13.9 per cent of the victims had co-morbidities while 1.5 per cent had no co-morbidity.

Among the patients aged below 45 years, those with co-morbidities accounted for 8.8 per cent of fatalities while 0.2 per cent did not have any co-morbidity.

The government said while the elderly and people with co-morbidities were more vulnerable and needed to take extra precautions, the young must not become complacent as even they are at risk of infection and are also potential carriers of the virus.



Source link

LEAVE A REPLY